All Stories

  1. Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier) [Corrigendum]

    Article • Cancer Management and Research, June 2019, Dove Medical Press

    Professor Mario Scartozzi, Dr Massimiliano Mistrangelo, Lorenzo Fornaro, Pierfrancesco Franco

  2. Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials

    Article • OncoTargets and Therapy, April 2019, Dove Medical Press

    Professor Mario Scartozzi

  3. Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier)

    Article • Cancer Management and Research, April 2019, Dove Medical Press

    Professor Mario Scartozzi, Dr Massimiliano Mistrangelo, Lorenzo Fornaro, Pierfrancesco Franco

  4. BRAF-mutant colorectal cancer, a different breed evolving

    Article • Expert Review of Molecular Diagnostics, May 2018, Taylor & Francis

    Professor Mario Scartozzi, Pina Ziranu

  5. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

    Article • The Oncologist, August 2017, Alphamed Press

    Professor Mario Scartozzi

  6. Immunotherapy for colorectal cancer: where are we heading?

    Article • Expert Opinion on Biological Therapy, April 2017, Taylor & Francis

    Oronzo Brunetti, Professor Mario Scartozzi

  7. Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?

    Article • Critical Reviews in Oncology/Hematology, April 2016, Elsevier

    Professor Mario Scartozzi

  8. Hypothyroidism and thyroid autoimmunity in metastatic renal cell carcinoma patients treated with sunitinib: 2 years follow-up of long survivors from a sigle centre experience

    Article • February 2016

    Professor Mario Scartozzi

  9. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy

    Article • Gastric Cancer, January 2016, Springer Science + Business Media

    Professor Mario Scartozzi

  10. Three drugs vs two drugs first-line chemotherapy regimen in advanced gastric cancer patients: a retrospective analysis

    Article • SpringerPlus, December 2015, Springer Science + Business Media

    Professor Mario Scartozzi

  11. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib

    Article • Expert Opinion on Pharmacotherapy, October 2015, Informa Healthcare

    Professor Mario Scartozzi

  12. Metastatic gastric cancer in the last two decades: goals achieved and future promises

    Article • Future Oncology, October 2015, Future Medicine

    Professor Mario Scartozzi

  13. Steps ahead in the treatment of advanced colorectal cancer: past, current and possible future scenarios

    Article • Future Oncology, October 2015, Future Medicine

    Professor Mario Scartozzi

  14. Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer

    Article • British Journal of Cancer, September 2015, Nature

    Professor Mario Scartozzi

  15. Metronomic chemotherapy from rationale to clinical studies: A dream or reality?

    Article • Critical Reviews in Oncology/Hematology, July 2015, Elsevier

    Professor Mario Scartozzi

  16. Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer

    Article • Expert Opinion on Investigational Drugs, June 2015, Informa Healthcare

    Professor Mario Scartozzi

  17. Prognostic Value for Incidental Antihypertensive Therapy With β-Blockers in Metastatic Colorectal Cancer

    Article • Medicine, June 2015, Wolters Kluwer Health

    Professor Mario Scartozzi

  18. The distinctive molecular, pathological and clinical characteristics ofBRAF-mutant colorectal tumors

    Article • Expert Review of Molecular Diagnostics, May 2015, Taylor & Francis

    Professor Mario Scartozzi

  19. Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab

    Article • Journal of Translational Medicine, May 2015, Springer Science + Business Media

    Professor Mario Scartozzi

  20. Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology

    Article • OncoTargets and Therapy, May 2015, Dove Medical Press

    Professor Mario Scartozzi

  21. Recent Aspects of Sunitinib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma: a Systematic Review of the Literature

    Article • Current Urology Reports, January 2015, Springer Science + Business Media

    Professor Mario Scartozzi

  22. Beyond RAS: The Role of Epidermal Growth Factor Receptor (EGFR) and its Network in the Prediction of Clinical Outcome During Anti-EGFR Treatment in Colorectal Cancer Patients

    Article • Current Drug Targets, December 2014, Bentham Science Publishers

    Professor Mario Scartozzi

  23. Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis

    Article • Expert Opinion on Biological Therapy, November 2014, Informa Healthcare

    Professor Mario Scartozzi

  24. Selected news from the 2014 Genitourinary Cancers Symposium: translating novel strategies into clinical practice

    Article • Future Oncology, November 2014, Future Medicine

    Professor Mario Scartozzi

  25. Perspectives from American Society of Clinical Oncology: translational and clinical research highlights in breast and colorectal cancers

    Article • Future Oncology, October 2014, Future Medicine

    Professor Mario Scartozzi

  26. The “angiogenetic ladder”, step-wise angiogenesis inhibition in metastatic colorectal cancer

    Article • Cancer Treatment Reviews, September 2014, Elsevier

    Professor Mario Scartozzi

  27. Pharmacogenomics of cetuximab in metastatic colorectal carcinoma

    Article • Pharmacogenomics, September 2014, Future Medicine

    Professor Mario Scartozzi

  28. Natural History of Malignant Bone Disease in Hepatocellular Carcinoma: Final Results of a Multicenter Bone Metastasis Survey

    Article • PLoS ONE, August 2014, PLOS

    Professor Mario Scartozzi

  29. The role of Micro-RNAs in Hepatocellular Carcinoma: From Molecular Biology to Treatment

    Article • Molecules, May 2014, MDPI AG

    Professor Mario Scartozzi

  30. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey

    Article • Expert Opinion on Investigational Drugs, May 2014, Informa Healthcare

    Professor Mario Scartozzi

  31. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study

    Article • International Journal of Cancer, February 2014, Wiley

    Professor Mario Scartozzi

  32. The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management

    Article • BMC Cancer, February 2014, Springer Science + Business Media

    Professor Mario Scartozzi

  33. Tumor angiogenesis genotyping and efficacy of first-line chemotherapy in metastatic gastric cancer patients

    Article • Pharmacogenomics, December 2013, Future Medicine

    Professor Mario Scartozzi

  34. The Response of Breast Cancer Cells to Mesenchymal Stem Cells

    Article • Plastic & Reconstructive Surgery, December 2013, Wolters Kluwer Health

    Professor Mario Scartozzi

  35. Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey

    Article • Expert Opinion on Pharmacotherapy, November 2013, Informa Healthcare

    Professor Mario Scartozzi

  36. Clinical Evidence for Three Distinct Gastric Cancer Subtypes: Time for a New Approach

    Article • PLoS ONE, November 2013, PLOS

    Professor Mario Scartozzi

  37. Molecular biomarkers of resistance to anti-EGFR treatment in metastatic colorectal cancer, from classical to innovation

    Article • Critical Reviews in Oncology/Hematology, November 2013, Elsevier

    Professor Mario Scartozzi

  38. Cancer Stem Cell Gene Profile as Predictor of Relapse in High Risk Stage II and Stage III, Radically Resected Colon Cancer Patients

    Article • PLoS ONE, September 2013, PLOS

    Professor Mario Scartozzi

  39. Role of β4 integrin inHER-3-negative,K-RASwild-type metastatic colorectal tumors receiving cetuximab

    Article • Future Oncology, August 2013, Future Medicine

    Professor Mario Scartozzi

  40. The Tower of Babel of liver metastases from colorectal cancer: Are we ready for one language?

    Article • Critical Reviews in Oncology/Hematology, March 2013, Elsevier

    Professor Mario Scartozzi

  41. Role of Vascular Endothelial Growth Factor (VEGF) and VEGF-R Genotyping in Guiding the Metastatic Process in pT4a Resected Gastric Cancer Patients

    Article • PLoS ONE, July 2012, PLOS

    Professor Mario Scartozzi

  42. Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab

    Article • Journal of Translational Medicine, April 2012, Springer Science + Business Media

    Professor Mario Scartozzi

  43. The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management

    Article • PLoS ONE, March 2012, PLOS

    Professor Mario Scartozzi

  44. Adjuvant Treatment After Surgical Resection

    Article • January 2012, Springer Science + Business Media

    Professor Mario Scartozzi

  45. Phase II study of pharmacogenetic-tailored therapy in elderly colorectal cancer patients

    Article • Digestive and Liver Disease, January 2012, Elsevier

    Professor Mario Scartozzi

  46. Palliative Treatment

    Article • January 2012, Springer Science + Business Media

    Professor Mario Scartozzi

  47. Adenocarcinoma arising from ileoanal J-pouch mucosa

    Article • Inflammatory Bowel Diseases, June 2011, Oxford University Press (OUP)

    Professor Mario Scartozzi

  48. Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options

    Article • Cancer Treatment Reviews, May 2011, Elsevier

    Professor Mario Scartozzi

  49. The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis

    Article • Digestive and Liver Disease, March 2011, Elsevier

    Professor Mario Scartozzi

  50. 5-fluorouracil pharmacogenomics: still rocking after all these years?

    Article • Pharmacogenomics, February 2011, Future Medicine

    Professor Mario Scartozzi

  51. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial

    Article • Cancer Chemotherapy and Pharmacology, September 2010, Springer Science + Business Media

    Professor Mario Scartozzi

  52. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan

    Article • International Journal of Cancer, August 2010, Wiley

    Professor Mario Scartozzi

  53. Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?

    Article • Lung Cancer, June 2010, Elsevier

    Professor Mario Scartozzi

  54. Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy

    Article • Current Oncology Reports, March 2010, Springer Science + Business Media

    Professor Mario Scartozzi

  55. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis

    Article • Journal of Experimental & Clinical Cancer Research, January 2010, Springer Science + Business Media

    Professor Mario Scartozzi

  56. Locally Advanced Rectal Cancer Patients Receiving Radio-Chemotherapy: A Novel Clinical–Pathologic Score Correlates With Global Outcome

    Article • International Journal of Radiation Oncology*Biology*Physics, December 2009, Elsevier

    Professor Mario Scartozzi

  57. Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2

    Article • Expert Opinion on Pharmacotherapy, September 2009, Informa Healthcare

    Professor Mario Scartozzi

  58. Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives

    Article • Cancer Treatment Reviews, August 2009, Elsevier

    Professor Mario Scartozzi

  59. Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1

    Article • Expert Opinion on Pharmacotherapy, July 2009, Informa Healthcare

    Professor Mario Scartozzi

  60. Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions

    Article • Critical Reviews in Oncology/Hematology, March 2009, Elsevier

    Professor Mario Scartozzi

  61. Chemotherapy and Radiotherapy in Pancreatic Cancer

    Article • January 2009, Springer Science + Business Media

    Professor Mario Scartozzi

  62. Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis

    Article • BMC Cancer, January 2009, Springer Science + Business Media

    Professor Mario Scartozzi

  63. Pancreatic cancer: Progress in cancer therapy

    Article • Critical Reviews in Oncology/Hematology, July 2008, Elsevier

    Professor Mario Scartozzi

  64. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial

    Article • The Lancet Oncology, January 2008, Elsevier

    Professor Mario Scartozzi

  65. COX-2 and NF-KB Overexpression Is Common in Pancreatic Cancer but Does Not Predict for COX-2 Inhibitors Activity in Combination With Gemcitabine and Oxaliplatin

    Article • American Journal of Clinical Oncology, October 2007, Wolters Kluwer Health

    Professor Mario Scartozzi

  66. “Biliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature review” [Cancer Treatment Reviews 32(5) (2006) 333–347]

    Article • Cancer Treatment Reviews, August 2007, Elsevier

    Professor Mario Scartozzi

  67. Chemotherapy for advanced gastric cancer: across the years for a standard of care

    Article • Expert Opinion on Pharmacotherapy, April 2007, Informa Healthcare

    Professor Mario Scartozzi

  68. Biliary tract cancers: Molecular profiling as a tool for treatment decisions. A literature review

    Article • Cancer Treatment Reviews, August 2006, Elsevier

    Professor Mario Scartozzi

  69. Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients

    Article • Lung Cancer, July 2006, Elsevier

    Professor Mario Scartozzi

  70. Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice

    Article • Expert Opinion on Therapeutic Targets, March 2006, Informa Healthcare

    Professor Mario Scartozzi

  71. A cost–benefit analysis of chemotherapy for gastric cancer

    Article • Expert Opinion on Pharmacotherapy, October 2004, Informa Healthcare

    Professor Mario Scartozzi

  72. Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches

    Article • Cancer Treatment Reviews, August 2004, Elsevier

    Professor Mario Scartozzi

  73. Gastric cancer treatment: a systematic review

    Article • Oncology Reports, April 2004, Spandidos Publications

    Professor Mario Scartozzi

  74. Predictive and Prognostic Role of E-Cadherin Protein Expression in Patients with Advanced Gastric Carcinomas Treated with Palliative Chemotherapy

    Article • Tumor Biology, January 2004, Springer Science + Business Media

    Professor Mario Scartozzi, Prof Mauro Magnani